Clinical Trials Browser

Phase 1 × MK 2206 × CNS × Clear all

NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Phase 1 Completed

BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms